- Home
- LCTX vs EM Comparison
LCTX vs EM Comparison
Compare LCTX & EM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- EM
- Stock Information
- Founded
- LCTX 1990
- EM 2017
- Country
- LCTX United States
- EM China
- Employees
- LCTX N/A
- EM N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- EM Other Consumer Services
- Sector
- LCTX Health Care
- EM Consumer Discretionary
- Exchange
- LCTX Nasdaq
- EM Nasdaq
- Market Cap
- LCTX 274.0M
- EM 286.5M
- IPO Year
- LCTX N/A
- EM 2021
- Fundamental
- Price
- LCTX $1.73
- EM $1.34
- Analyst Decision
- LCTX Strong Buy
- EM Hold
- Analyst Count
- LCTX 4
- EM 1
- Target Price
- LCTX $4.25
- EM $1.25
- AVG Volume (30 Days)
- LCTX 1.9M
- EM 704.8K
- Earning Date
- LCTX 11-13-2025
- EM 11-26-2025
- Dividend Yield
- LCTX N/A
- EM N/A
- EPS Growth
- LCTX N/A
- EM N/A
- EPS
- LCTX N/A
- EM N/A
- Revenue
- LCTX $10,914,000.00
- EM $259,541,587.00
- Revenue This Year
- LCTX N/A
- EM $3.30
- Revenue Next Year
- LCTX $176.00
- EM $5.26
- P/E Ratio
- LCTX N/A
- EM N/A
- Revenue Growth
- LCTX 76.43
- EM N/A
- 52 Week Low
- LCTX $0.37
- EM $0.59
- 52 Week High
- LCTX $1.83
- EM $1.45
- Technical
- Relative Strength Index (RSI)
- LCTX 69.14
- EM 54.36
- Support Level
- LCTX $1.64
- EM $1.31
- Resistance Level
- LCTX $1.77
- EM $1.39
- Average True Range (ATR)
- LCTX 0.11
- EM 0.03
- MACD
- LCTX -0.00
- EM -0.01
- Stochastic Oscillator
- LCTX 75.00
- EM 66.67
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.